Casting light on multiple sclerosis heterogeneity: The role of HLA-DRB1 on spinal cord pathology

Brain

Volumn 136, Issue 4, 2013, Pages 1025-1034

  Deluca, Gabriele C ^a   Alterman, Rose ^a   Martin, Jenny L ^a   Mittal, Arunesh ^a   Blundell, Samkeliso ^a   Bird, Shannon ^a   Beale, Harry ^a   Hong, Lai San ^b   Esiri, Margaret M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

genetics; multiple sclerosis; outcome; pathology; spinal cord

Indexed keywords

HLA DRB1 ANTIGEN; MYELIN;

ALLELE; ARTICLE; AUTOPSY; CERVICAL SPINE; COHORT ANALYSIS; DEMYELINATION; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMBAR SPINE; MALE; MENINGITIS; MULTIPLE SCLEROSIS; NERVE FIBER; PRIORITY JOURNAL; THORACIC SPINE;

EID: 84876049193     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt031     Document Type: Article

References (30)

1. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010; 68: 465-76.
2. Barcellos LF, Oksenberg JR, Green AJ, Bucher P, Rimmler JB, Schmidt S, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125: 150-8.
3. Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology 2009; 72: 1495-503.
4. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135: 2925-37.
5. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004; 127: 1009-18.
6. DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007; 104: 20896-901.
7. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129: 1507-16.
8. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 2006; 111: 289-99.
9. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 2011; 93: 1-12.
10. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
11. Fog T. Topographic distribution of plaques in the spinal cord in multiple sclerosis. AMA Arch Neurol Psychiatry 1950; 63: 382-414.
12. Kooi EJ, van Horssen J, Witte ME, Amor S, Bo L, Dijkstra CD, et al. Abundant extracellular myelin in the meninges of patients with multiple sclerosis. Neuropathol Appl Neurobiol 2009; 35: 283-95.
13. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-94.
14. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-12.
15. Loeffler C, Dietz K, Schleich A, Schlaszus H, Stoll M, Meyermann R, et al. Immune surveillance of the normal human CNS takes place in dependence of the locoregional blood-brain barrier configuration and is mainly performed by CD3( + )/CD8( + ) lymphocytes. Neuropathology 2011; 31: 230-8.
16. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000; 48: 211-9.
17. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-9.
18. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011; 76: 686-92.
19. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009; 132: 250-9.
20. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4: 151-62.
21. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
22. Qiu W, Raven S, James I, Luo Y, Wu J, Castley A, et al. Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011; 300: 114-9.
23. Ramagopalan SV, Deluca GC, Degenhardt A, Ebers GC. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008; 201-202: 183-99.
24. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-9.
25. Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, et al. HLA-DRB1 1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009; 66: 1531-6.
26. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29: 14965-79.
27. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406-11.
28. Trotter JL, Wegescheide CL, Garvey WF. Regional studies of myelin proteins in human brain and spinal cord. Neurochem Res 1984; 9: 133-46.
29. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994; 179: 279-90.
30. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002; 61: 23-32.